Whittier Trust Co. Sells 104 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Whittier Trust Co. lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,820 shares of the pharmaceutical company’s stock after selling 104 shares during the period. Whittier Trust Co.’s holdings in Vertex Pharmaceuticals were worth $810,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Activest Wealth Management bought a new stake in shares of Vertex Pharmaceuticals in the first quarter valued at about $25,000. Clal Insurance Enterprises Holdings Ltd lifted its stake in Vertex Pharmaceuticals by 450.0% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 45 shares during the period. Flaharty Asset Management LLC bought a new position in Vertex Pharmaceuticals during the first quarter worth about $32,000. American National Bank & Trust lifted its stake in Vertex Pharmaceuticals by 515.4% during the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock worth $36,000 after purchasing an additional 67 shares during the period. Finally, University of Texas Texas AM Investment Management Co. bought a new position in Vertex Pharmaceuticals during the first quarter worth about $46,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Down 0.9%

NASDAQ:VRTX opened at $422.63 on Friday. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $519.88. The firm has a 50 day moving average of $398.38 and a 200-day moving average of $435.23. The stock has a market capitalization of $108.36 billion, a P/E ratio of 30.21 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company had revenue of $2.94 billion during the quarter, compared to analysts’ expectations of $2.90 billion. During the same quarter in the previous year, the company posted ($12.83) earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analysts Set New Price Targets

VRTX has been the subject of a number of analyst reports. Wells Fargo & Company upgraded shares of Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 price target for the company in a research note on Wednesday, August 6th. Weiss Ratings restated a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, October 8th. UBS Group set a $553.00 price target on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Leerink Partnrs upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 25th. Finally, Evercore ISI cut their price target on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a research note on Thursday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $494.38.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs purchased 5,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was acquired at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.